Immunology & Autoimmune
Part of Biotech - Drug Development
 JNJ | Johnson & Johnson | $0.5t | $254.38 | +4.0% | 9.7M |
 ABBV | ABBVIE INC. | $384.7b | $252.95 | +4.1% | 11.1M |
 AMGN | Amgen Inc | $181.8b | $357.17 | +1.4% | 1.7M |
 BMY | Bristol-Myers Squibb Co. | $116.8b | $57.40 | +3.8% | 9.2M |
 REGN | Regeneron Pharmaceuticals Inc | $64.5b | $629.25 | +2.1% | 689.1K |
 ROIV | Roivant Sciences Ltd. Common Shares | $21.6b | $34.06 | +0.1% | 6.4M |
 IBRX | ImmunityBio, Inc. Common Stock | $7.9b | $8.48 | +11.6% | 23.1M |
 IMVT | Immunovant, Inc. Common Stock | $6.8b | $38.63 | +1.5% | 1.1M |
 PTGX | Protagonist Therapeutics, Inc | $6.4b | $121.83 | -0.6% | 860.4K |
 SYRE | Spyre Therapeutics, Inc. Common Stock | $6.4b | $87.88 | -1.1% | 1.7M |
 APGE | Apogee Therapeutics, Inc. Common Stock | $6.2b | $132.56 | -0.0% | 3.9M |
 TGTX | TG Therapeutics, Inc. | $5.8b | $55.50 | +4.1% | 3.1M |
 APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
 DNTH | Dianthus Therapeutics, Inc. Common Stock | $5.1b | $79.88 | +4.2% | 2.2M |
 ORKA | Oruka Therapeutics, Inc. Common Stock | $3.5b | $90.47 | +4.5% | 1.9M |
 RCUS | Arcus Biosciences, Inc. | $3.2b | $31.36 | +2.5% | 1.6M |
 ALMS | Alumis Inc. Common Stock | $2.8b | $26.37 | +5.4% | 1.7M |
 ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $2.7b | $26.88 | +1.1% | 1.1M |
 VERA | Vera Therapeutics, Inc. Class A Common Stock | $2.5b | $42.94 | +4.9% | 2.3M |
 CLDX | Celldex Therapeutics, Inc | $2.5b | $32.89 | +3.5% | 1.4M |
 NKTR | Nektar Therapeutics | $2.2b | $63.62 | +2.4% | 1.1M |
 AUPH | Aurinia Pharmaceuticals Inc | $2.0b | $17.20 | -1.8% | 2.0M |
 ADMA | ADMA Biologics, Inc. | $1.8b | $8.72 | 0.0% | 2.2M |
 ANAB | AnaptysBio, Inc. Common Stock | $1.7b | $62.49 | +5.8% | 576.8K |
 BHVN | Biohaven Ltd. | $1.7b | $15.89 | +3.2% | 5.1M |
 MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.4b | $20.07 | -0.5% | 1.3M |
 SEPN | Septerna, Inc. Common Stock | $1.4b | $37.24 | +7.7% | 745.1K |
 ZBIO | Zenas BioPharma, Inc. Common Stock | $1.2b | $26.66 | +5.1% | 1.4M |
 DBVT | DBV Technologies S.A. | $1.1b | $16.05 | +0.2% | 194.6K |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.0b | $13.29 | +3.3% | 1.3M |
 JBIO | Jade Biosciences, Inc. Common Stock | $1.0b | $22.02 | +0.8% | 1.0M |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $17.93 | -0.8% | 823.6K |
 ANNX | Annexon, Inc. Common Stock | $0.9b | $5.52 | +6.0% | 5.0M |
 XNCR | Xencor, Inc. | $0.9b | $15.32 | +2.4% | 929.6K |
 AVTX | Avalo Therapeutics, Inc. Common Stock | $0.8b | $18.00 | +0.8% | 1.8M |
 EVMN | Evommune, Inc. | $0.8b | $25.09 | +4.4% | 637.8K |
 IMMX | Immix Biopharma, Inc. Common Stock | $0.6b | $9.97 | +2.6% | 1.5M |
 ACRS | Aclaris Therapeutics, Inc. | $0.6b | $4.90 | +1.8% | 2.3M |
 CLYM | Climb Bio, Inc. Common Stock | $0.6b | $13.12 | +3.9% | 958.4K |
 CABA | Cabaletta Bio, Inc. Common Stock | $0.6b | $3.03 | +3.8% | 7.4M |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.6b | $38.19 | +4.4% | 188.9K |
 KYTX | Kyverna Therapeutics, Inc. Common Stock | $0.5b | $8.29 | +3.0% | 822.2K |
 STTK | Shattuck Labs, Inc. Common Stock | $456.2m | $6.41 | +8.0% | 2.3M |
 UPB | Upstream Bio, Inc. Common Stock | $455.0m | $6.75 | +6.3% | 463.7K |
 IPSC | Century Therapeutics, Inc. Common Stock | $441.9m | $2.38 | +1.7% | 2.2M |
 FBRX | Forte Biosciences, Inc. Common Stock | $390.5m | $20.88 | +11.5% | 458.6K |
 ENTA | Enanta Pharmaceuticals, Inc | $382.7m | $14.67 | +3.9% | 201.7K |
 PALI | Palisade Bio, Inc. Common Stock | $368.4m | $1.89 | +5.0% | 3.3M |
 ZURA | Zura Bio Limited Class A Ordinary Shares | $355.8m | $5.41 | +18.5% | 2.2M |
 IFRX | InflaRx N.V. Common Stock | $353.5m | $1.92 | +3.5% | 1.3M |